Seek Returns

RDY vs. ZTS: Dr. Reddy's Laboratories vs. Zoetis Stock Comparison

How do Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Zoetis (ZTS) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
Profile ItemRDYZTS
NameDr. Reddy's Laboratories Ltd. ADRZoetis Inc. Class A Common Stock
Country/RegionIndiaUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization12.43 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateApril 11, 2001February 1, 2013
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

RDY
ZTS
GSPC
Loading price history…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
MetricRDYZTS
Total Return (1Y)12.49%-30.10%
Total Return (3Y, Annualized)5.76%-20.42%
Total Return (5Y, Annualized)4.06%-16.87%

Risk Profile

Drawdown History

RDY
ZTS
GSPC
Loading price history…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
MetricRDYZTS
Volatility (1Y, Annualized)27.06%38.23%
Beta (5Y)0.300.66
Max Drawdown (5Y)-32.01%-70.45%
Avg. Volume (3M)2.89M4.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RDY and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
MetricRDYZTS
Sharpe Ratio (1Y)0.30-0.90
Sortino Ratio (1Y)0.43-1.10

Profitability

ROE (TTM)

Both Dr. Reddy's Laboratories (RDY) at 7.34% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.34%

Max
109.18%
RDY
7.34%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Zoetis (ZTS) at 26.41% keeps the most of each sales dollar — above its industry’s net margin range — and Dr. Reddy's Laboratories (RDY) at 8.49% also retains a top-quartile share.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.49%

Max
18.05%
RDY
8.49%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Zoetis (ZTS) at 38.19% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.73%

Max
83.12%
Q3
14.77%
RDY
14.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
MetricRDYZTS
ROE (TTM)7.34%57.63%
ROA (TTM)3.37%14.87%
Net Margin (TTM)8.49%26.41%
Operating Margin (TTM)14.73%38.19%
Gross Margin (TTM)49.49%71.65%

Growth

Revenue Growth

Both Dr. Reddy's Laboratories (RDY) at 3.19% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Dr. Reddy's Laboratories (RDY) at -24.14% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
MetricRDYZTS
Revenue Growth (YoY)3.19%2.28%
Revenue Growth (3Y CAGR)10.96%5.42%
EPS Growth (YoY)-24.14%10.05%
EPS Growth (3Y CAGR)-1.72%10.27%

Financial Strength

Current Ratio (MRQ)

Both Dr. Reddy's Laboratories (RDY) at 1.93 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.93

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RDY
1.93
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Dr. Reddy's Laboratories (RDY) at 0.19 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max
1.42
Q3
0.65
RDY
0.19
Median
0.15
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
MetricRDYZTS
Current Ratio (MRQ)1.932.35
Debt / Equity (MRQ)0.192.80
Net Debt / EBITDA-0.081.92

Dividends

Dividend Yield (TTM)

Both Dr. Reddy's Laboratories (RDY) at 55.06% and Zoetis (ZTS) at 2.55% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

55.06%

RDY
55.06%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Dr. Reddy's Laboratories (RDY) at 22.72% and Zoetis (ZTS) at 35.24% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.72%

RDY
22.72%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
MetricRDYZTS
Dividend Yield (TTM)55.06%2.55%
Dividend Payout Ratio (TTM)22.72%35.24%

Valuation

P/E Ratio (TTM)

Both Dr. Reddy's Laboratories (RDY) at 41.42 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.42

Max
85.34
Q3
43.46
RDY
41.42
Median
26.69
Q1
13.30
Min
0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Zoetis (ZTS) at 3.40 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
RDY
0.04
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Zoetis (ZTS) at 9.80 sits in the upper P/B ratio quartile, and Dr. Reddy's Laboratories (RDY) at 18.16 prices even higher, above its industry range.

RDY

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.16

RDY
18.16
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Dr. Reddy's Laboratories (RDY) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Dr. Reddy's Laboratories (RDY) and Zoetis (ZTS)
MetricRDYZTS
P/E Ratio (TTM)41.4213.50
P/S Ratio (TTM)0.043.40
P/B Ratio (MRQ)18.169.80
Free Cash Flow Yield (TTM)-53.03%6.36%